ZOLEDRONIC ACID FOR INJECTION 4 MG

Indications

• Osteoporosis
• Paget's disease
• Prevention of skeletal-related events in patients with bone metastases
• Hypercalcemia of malignancy

Dosage

Children: The safety and efficacy of zoledronic acid in children have not been established, and thus specific pediatric dosing information is not available. Refer to the B

Adults: The typical adult dosage for osteoporosis is a single intravenous infusion of 5 mg once a year. For Paget's disease, a single dose of 5 mg is recommended, with the possibility of retreatment after 1 year if necessary.

Mechanism of action

Zoledronic acid binds to hydroxyapatite in bone, where it is taken up by osteoclasts during bone resorption. Once inside the osteoclasts, it disrupts their function by inhibiting the mevalonate pathway, specifically targeting farnesyl diphosphate synthase. This inhibition prevents the prenylation of GTP-binding proteins, leading to osteoclast apoptosis. Additionally, it interferes with the formation of podosomes, structures necessary for osteoclast attachment to bone, further reducing bone resorption.

Pharmacodynamics

Zoledronic acid inhibits osteoclast function, thereby preventing bone resorption. It has a wide therapeutic window, meaning that significant adverse effects are unlikely even in cases of overdose. Despite its safety profile, patients must be monitored for potential electrolyte imbalances, renal dysfunction, and rare but serious side effects such as osteonecrosis of the jaw and atypical femoral fractures.

Pharmacokinetics

Zoledronic acid exhibits a long half-life, with an extended duration of action that allows for infrequent dosing. Following intravenous administration, it is rapidly distributed in the bone and has minimal systemic exposure. The drug is predominantly eliminated via the kidneys, necessitating caution in patients with renal impairment.

Adverse effects

• Hypocalcemia
• Renal impairment
• Osteonecrosis of the jaw
• Atypical femoral fractures
• Bronchoconstriction
• Hepatic impairment
• Electrolyte deficiencies

Precautions

• Monitor renal function
• Assess serum calcium levels
• Evaluate for risk factors of osteonecrosis of the jaw

Pregnancy

Use is not recommended due to potential risks to the fetus, including embryo-fetal toxicity.

Breast-feeding

Caution is advised as it is not known whether zoledronic acid is excreted in human milk.

Storage

Store at room temperature, protect from light and moisture. Do not freeze.

Formulations

• Intravenous solution

Mechanism of action

Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act. Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin. Etidronic acid also inhibits V-ATPases in the osteoclast, though the exact subunits are unknown, preventing F-actin from forming podosomes. Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption. Nitrogen containing bisphosphonates such as zoledronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate. These components are essential for post-translational prenylation of GTP-binding proteins like Rap1. The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis. zoledronate also activated caspases which further contribute to apoptosis.

Pharmacodynamics

Zoledronic acid is a third generation, nitrogen containing bisphosphonate that inhibits osteoclast function and prevents bone resorption. The therapeutic window is wide as patients are unlikely to suffer severe effects from overdoses and the duration of action is long. Patients should be counselled regarding the risk of electrolyte deficiencies, renal impairment, osteonecrosis of the jaw, atypical femoral fractures, bronchoconstriction, hepatic impairment, hypocalcemia, and embryo-fetal toxicity.